Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Adzynma Prior Auth Coverage Update | Op…
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Adzynma (ADAMTS13, recombinant-krhn) — Medical prior authorization and coverage criteria for congenital TTP

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical prior authorization and coverage criteria for Adzynma used as prophylactic or on‑demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP) for CareSource Arkansas PASSE.

    Policy Summary
    PayerCareSource
    PolicyAdzynma (ADAMTS13, recombinant-krhn) — coverage criteria for cTTP
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateJul 1, 2026
    Last ReviewFeb 3, 2026
    Next Review DateFeb 3, 2026
    Key ActionObtain medical prior authorization with documentation: hematologist involvement, genetic confirmation of ADAMTS13 mutation, and plasma ADAMTS13 activity <10%.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 moinitial approval duration when criteria met
    12 moreapproval duration when reauthorization criteria met
    <10%required ADAMTS13 activity
    40 IU/kgprophylaxis dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    40/20/15 IU/kgon-demand dosing

    Coverage Criteria for Adzynma (ADAMTS13, recombinant-krhn)

    Initial Therapy

    Covered when ALL of the following are met for initial authorization:

    Initial authorization criteria: 1) Medication prescribed by or in consultation with a hematologist; AND 2) Member has a diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP) confirmed by BOTH: (a) genetic test results demonstrating ADAMTS13 gene mutation; AND (b) plasma ADAMTS13 activity level <10% of normal (<10 IU/dL)); AND 3) Dosage consistent with policy: Prophylaxis 40 IU/kg IV once every other week (may adjust to once weekly) OR On‑Demand dosing 40 IU/kg day 1, 20 IU/kg day 2, 15 IU/kg day 3 and beyond until two days after the acute event is resolved. If all requirements are met, approve for 6 months.

    Continuation Therapy / Reauthorization

    Reauthorization covered when ALL of the following are met:

    Reauthorization criteria: Chart notes must show improvement or stabilized signs and symptoms of disease such as fewer acute TTP events, increased ADAMTS13 activity, or increased platelet count with treatment.

    If met, approve for additional 12 months.

    Coverage of Adzynma (ADAMTS13, recombinant-krhn) is provided when the documented clinical presentation and supporting tests satisfy the medical necessity criteria in this policy. Specifically, initial and continuation authorizations require documentation that the medication is being used to treat congenital thrombotic thrombocytopenic purpura (cTTP) and that prescriber and diagnostic requirements in the criteria are met. Off‑label uses (indications not listed in this policy) must be evaluated under the plan’s Off‑Label policy and do not meet the medical necessity criteria described here unless explicitly approved through that process.

    Use of Adzynma for indications other than congenital TTP as described in this document is considered not medically necessary. Requests for other diagnoses should be referred to the Off‑Label policy and will not be approved under the standard coverage criteria herein.

    Initial Therapy Requirements and Dosing

    Initial Therapy

    Initial dosing and prescriber requirements

    Initial therapy: Prescribed by or in consultation with a hematologist; genetic test results demonstrating ADAMTS13 gene mutation; plasma ADAMTS13 activity <10% of normal (<10 IU/dL); dosing per policy: Prophylaxis 40 IU/kg IV every other week (may adjust to once weekly); On‑Demand: 40 IU/kg on day 1, 20 IU/kg on day 2, 15 IU/kg on day 3 and beyond until two days after the acute event is resolved.

    Initial approval duration: 6 months.

    Adzynma dosing — prophylaxis and on‑demand schedules
    Prophylaxis dosing40 IU/kg IV every other week (may adjust to once weekly)
    On‑demand day 140 IU/kg IV on day 1
    On‑demand day 220 IU/kg IV on day 2

    Reauthorization and Ongoing Use

    Reauthorization

    Reauthorization requirements for ongoing coverage

    Reauthorization: Chart notes must document clinical improvement or stability with treatment, e.g., fewer acute TTP events, increased ADAMTS13 activity, or increased platelet count.

    Approval for 12 months if criteria met.

    Provider Requirements and Administrative Actions

    Prior Authorization

    Medical prior authorization required

    Adzynma (ADAMTS13, recombinant-krhn) requires medical prior authorization under the medical benefit for treatment of congenital TTP when policy criteria are met.

    Step Therapy

    No step therapy required

    This policy does not impose any step therapy requirements for Adzynma.

    Documentation Required

    Required documentation for initial request and reauthorization

    Initial authorization requests must include documentation that the medication was prescribed by or in consultation with a hematologist, genetic test results demonstrating an ADAMTS13 gene mutation, and a plasma ADAMTS13 activity level <10% of normal (<10 IU/dL). Reauthorization requests must include chart notes showing clinical improvement or stabilization (fewer acute TTP events, increased ADAMTS13 activity, or increased platelet count).

    Diagnostic and Laboratory Coding / Thresholds

    Plasma ADAMTS13 activity — required diagnostic threshold
    Required diagnostic thresholdPlasma ADAMTS13 activity <10% of normal (<10 IU/dL)
    Use in diagnosisMust be confirmed alongside genetic testing demonstrating ADAMTS13 gene mutation
    ContextThreshold is part of initial authorization requirements for cTTP

    Administration Setting

    Note

    IV administration — no site restriction specified

    Adzynma is administered intravenously; the policy specifies IV administration but does not further restrict the site of care (no additional infusion center/site limitations stated).

    Key Definitions

    cTTP (congenital thrombotic thrombocytopenic purpura) — definition and clinical context
    DefinitionHereditary deficiency of ADAMTS13 caused by ADAMTS13 gene mutations, resulting in markedly reduced ADAMTS13 activity and clinical TTP manifestations.
    PathophysiologyDeficiency of ADAMTS13 leads to accumulation of ultra‑large VWF multimers, platelet aggregation, microthrombi, hemolytic anemia, thrombocytopenia and organ dysfunction.
    Historical treatmentPlasma infusions were historically used to replace ADAMTS13 prior to availability of recombinant therapy.

    Quantity and Dosing Limits

    Adzynma — dosing limits and typical schedules
    Standard prophylaxis limit40 IU/kg IV every other week (may adjust to once weekly)
    On‑demand schedule40 IU/kg day 1, 20 IU/kg day 2, 15 IU/kg day 3 and beyond until two days after acute event resolved
    Administration routeIntravenous (IV)
    Approval duration when dosing meets policyInitial approval for 6 months

    Step Therapy Requirements

    StepRequirement
    No step therapy steps specifiedThis policy does not include any step therapy requirements for Adzynma; medical prior authorization and coverage criteria apply as outlined elsewhere in the policy.

    Background and Clinical Context

    Adzynma (ADAMTS13, recombinant-krhn) is a recombinant ADAMTS13 product indicated in this policy for enzyme replacement in patients with congenital thrombotic thrombocytopenic purpura (cTTP). cTTP is a hereditary deficiency of ADAMTS13 that results in accumulation of ultra‑large von Willebrand factor multimers, platelet aggregation, microthrombi formation, hemolytic anemia, thrombocytopenia and potential organ dysfunction. Historically, plasma infusions were used to replace ADAMTS13; Adzynma provides a targeted recombinant enzyme replacement option for prophylactic or on‑demand treatment in this population.

    Policy Summary
    PayerCareSource
    PolicyAdzynma (ADAMTS13, recombinant-krhn) — coverage criteria for cTTP
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateJul 1, 2026
    Last ReviewFeb 3, 2026
    Next Review DateFeb 3, 2026
    Key ActionObtain medical prior authorization with documentation: hematologist involvement, genetic confirmation of ADAMTS13 mutation, and plasma ADAMTS13 activity <10%.
    SourceLink
    On This Page
    Coverage Criteria for Adzynma (ADAMTS13, recombinant-krhn)Initial Therapy Requirements and DosingReauthorization and Ongoing UseProvider Requirements and Administrative ActionsDiagnostic and Laboratory Coding / ThresholdsAdministration SettingKey DefinitionsQuantity and Dosing LimitsStep Therapy RequirementsBackground and Clinical Context
    On‑demand day 3 and beyond15 IU/kg IV on day 3 and beyond until two days after the acute event is resolved
    • Prescriber: hematologist or consultation documentation
    • Genetic test results confirming ADAMTS13 gene mutation
    • Plasma ADAMTS13 activity level <10% of normal (<10 IU/dL) for initial requests
    • Reauthorization: chart notes demonstrating improvement or stability (fewer acute TTP events, increased ADAMTS13 activity, or increased platelet count)
    Denial Risk

    Denial triggers for Adzynma authorization

    Authorization may be denied if required documentation or coverage criteria are not provided — for example, lack of hematologist involvement, missing genetic confirmation of ADAMTS13 mutation, or plasma ADAMTS13 activity ≥10% of normal; similarly, failure to supply reauthorization chart notes showing improvement/stability can lead to denial.

    • No documentation of hematologist prescription or consultation
    • No genetic test demonstrating ADAMTS13 mutation
    • Plasma ADAMTS13 activity not shown to be <10% of normal
    • Missing reauthorization chart notes showing clinical improvement or stability